Table 2.

Association between serum selenium status and prostate cancer risk in the EPIC-Heidelberg nested case-control study (n = 740)

	Quartiles of serum selenium concentration (μg/L)				Continuous (per 10 μg/L)
	<78.9	78.9-87.0	87.0-95.0	≥95.0	Continuous (per 10 μg/L)
Cases/controls (n)	69/116	66/125	43/122	66/127
Crude OR^* (95% CI)	1.00	0.90 (0.58, 1.40)	0.60 (0.38, 0.95)	0.89 (0.58, 1.37)	0.92 (0.82, 1.04)
Adjusted OR^† (95% CI)	1.00	0.92 (0.59, 1.43)	0.61 (0.38, 0.98)	0.78 (0.49, 1.22)	0.89 (0.79, 1.01)
Excluding cases diagnosed during 1st year of follow-up (and matched controls)
Cases/controls (n)	68/112	59/116	40/117	64/119
Adjusted OR^† (95% CI)	1.00	0.87 (0.55, 1.37)	0.57 (0.35, 0.92)	0.79 (0.50, 1.25)	0.89 (0.78, 1.01)
High-grade prostate cancer
Cases/controls (n)	31/37	21/46	12/41	26/56
Adjusted OR^† (95% CI)	1.00	0.53 (0.25, 1.12)	0.34 (0.15, 0.79)	0.50 (0.24, 1.03)	0.84 (0.69, 1.02)
Low-grade prostate cancer
Cases/controls (n)	35/68	31/67	26/67	36/56
Adjusted OR^† (95% CI)	1.00	0.91 (0.48, 1.71)	0.75 (0.40, 1.41)	1.10 (0.58, 2.09)	0.96 (0.81, 1.15)

↵*Crude OR from conditional logistic regression stratified by matching factors (age group and time of recruitment).
↵^†Adjusted OR additionally adjusted for family history of prostate cancer, participation in PSA testing, smoking status, and vigorous physical activity.